Immunovia AB (IMMNOV.ST) Stock Analysis & Winston Score

Immunovia is a Swedish biotech company focused on developing blood tests to detect serious diseases at an early stage. Its main focus has been on pancreatic cancer, one of the hardest cancers to catch early because it rarely causes symptoms until it is very advanced. The company's lead product, IMMray PanCan-d, is designed to identify pancreatic cancer in high-risk patients before symptoms appear. Immunovia makes money by selling diagnostic tests, primarily targeting physicians and high-risk patient groups in the United States and Europe. The company is very small, with a market cap around $100 million, and is not yet profitable — its deeply negative margins show it is spending far more than it earns while trying to build commercial traction. The biggest risk is that the company may struggle to generate enough revenue to fund its operations, and it faces an ongoing challenge convincing healthcare systems and insurers to adopt and reimburse its test at scale.